eligibility_summary
Eligibility: Confirmed MS and no prior BRIUMVI, patients prescribed BRIUMVI but not yet given the initial 150 mg dose may enroll. Exclusions: any live/live-attenuated vaccine within 4 weeks or non-live vaccine within 2 weeks before first dose, active infections (e.g., HBV), participation in other interventional MS trials or planned concurrent MS DMT.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study type: Observational, real-world registry of adults with relapsing MS receiving BRIUMVI (ublituximab‑xiiy). Drug/intervention: BRIUMVI is an IV, glycoengineered type I anti‑CD20 monoclonal antibody (immunotherapy). Mechanism: Selectively binds CD20 on B cells and depletes them primarily via enhanced antibody‑dependent cellular cytotoxicity, with contributions from complement‑dependent cytotoxicity and apoptosis. Targets/cells/pathways: Pre‑B and mature CD20+ B lymphocytes (spares plasma cells), reducing B‑cell antigen presentation, costimulation, and proinflammatory cytokine signaling to dampen pathogenic adaptive immune activity in MS.